Lexaria Bioscience Completes DehydraTECH Animal Study #2 (GLP-1-A26-2) on Retatrutide and Amycretin June 9: Targeting Oral Formulation Enhancements and IP Claims on Next-Generation GLP-1s
Lexaria Bioscience (NASDAQ: LEXX) announced June 9, 2026 that dosing has been completed in Animal Study #2 (GLP-1-A26-2) evaluating its DehydraTECH oral peptide delivery platform with two next-generation GLP-1 drugs: Eli Lilly's retatrutide (triple GIP/GLP-1/glucagon agonist) and Novo Nordisk's amycretin (unimolecular GLP-1/amylin agonist). The study tested formulation enhancements designed to improve DehydraTECH performance and stake intellectual property claims on next-generation oral GLP-1 delivery. The data follows Lexaria's April 23 study launch and feeds the broader oral GLP-1 platform competition with Novo Nordisk's Wegovy pill (3M US prescriptions in 5 months) and Lilly's orforglipron (Foundayo, approved April 2026). Lexaria's industry update June 17 framed the oral GLP-1 pill segment as 'billions in new industry sales' potential.